Figure 5. Application of the protocol for characterization of site-specific N-glycan processing of recombinant glycoprotein therapeutics and serum glycoproteins.
(a–d) Site-specific N-glycan processing of the recombinant glycoprotein therapeutics IgG (a) and IgM (b), as well as the serum glycoproteins transferrin (c) and fetuin (d). A set of peptides with N+0, N+3, and N+203 modifications was displayed only when at least one of the three had a peak area of at least >5 × 108. Data were obtained from at least six independent experiments. Mean ± s.e.m. were plotted. d adapted from ref. 10, Nature Publishing Group.